What a buyer sees
OXFORD GENETICS LTD
Research and experimental development on biotechnology · London · 07617346
103staff · FY2023
15years trading
—oldest owner on file
£2.3Mcash at bank
Your turnover is on public record
filed£9.1Mfor the year to 2023
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff103
2021102 → 1032023
Cash at bank£2.3M
2021£1.3M → £2.3M2023
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£88,652in the middle half
£28,358£136,156£699,758
Debtor daysdays54in the middle half
1457178
Creditor daysdays10
1126130
Stock daysdaysnot on your filings
730102
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 4
- The newest accounts on file are 32 months oldAnyone looking at the company today is reading a year that has already ended. Whatever has improved since is invisible.
- A director resigned in the past yearA buyer will ask why, and will hear the answer from somewhere. Better from you.
- Headcount fell from 122 to 103A buyer sees the fall and not the reason. Deliberate tightening and losing people look identical on a filing.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 0
Nothing stands out yet from the filings alone.
What the register says
Owners
Nobody recorded with significant control.
Directors
- since 2021
- 58since 2025
- 60since 2025
| Year to | Turnover | Staff | Cash |
|---|---|---|---|
| 2023-12-31 | £9.1M | 103 | £2.3M |
| 2022-12-31 | £14M | 122 | £3.8M |
| 2021-12-31 | £3.3M | 102 | £1.3M |
A rough bracket, and why it is only that
0.4–0.9× sales£3.6M£8.2M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.